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GPR55 is a G-protein coupled receptor (GPCR) that was first discovered in 1990 
and deorphanized in 2006.  A potent agonist of GPR55 is the endogenous LPI and one 
antagonist is ML192.   Due to the diseases associated with GPR55, a more potent 
antagonist or agonist is required that can deactivate or activate the receptor in order to 
further elucidate the role and function of GPR55 in the body.  The focus of the research 
here in is the synthesis a variety of analogs of ML192 with the goal of finding a more 
potent antagonist than ML192. The synthesized analogs were subjected to biological 
assays and computational analysis.   Four different novel analogs were synthesized that 
further probed some structure-activity relationships 
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CHAPTER	I	
	
INTRODUCTION	
 
 
G-Protein Coupled Receptors (GPCRs) are integral transmembrane proteins that 
are found all over the body such as the central nervous system, lungs, and bone.1 GPCRs 
are one of the largest superfamily of proteins that consists of approximately 1000 types.i 
Due to their biological activity, 60% of pharmaceutical drugs target GPCRs.1 
GPR55 is a GPCR that was first identified and cloned in 1990 and deorphanized 
in 2006.2 GPR55 is composed of seven transmembrane helices (TMH, Figure 1). Some 
biological activities of GPR55 include inflammation, cancer, and pain.3,4 Studies showed 
that GPR55 is up regulated in a variety of cancers such as ovarian, breast, and pancreatic 
cancer.4 There is a direct correlation found between the progression of certain cancers 
and the amount of GPR55 activity.4   This makes GPR55 a potential drug target for 
various diseases and treatments.  
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A study was completed on knockout mice in order to determine the biological 
effects of GPR55.4  One of the effects in mice was long-term depression when higher 
levels of GPR55 was observed.4  Another study showed that GPR55 disrupts the 
activation of decidual cells, which leads to fetoplacental development.i5  GPR55 is 
expressed in the following types of cells: bone marrow, endothelial cells, and mast 
cells.6,4  The role that GPR55 has on psychological and physiological effects is not 
known but it is associated with many diseases, tissues, cells, and organs.   
Due to the impressive biological activity of GPR55, a screening of approximately 
300,000 compounds was completed by the Sanford-Burnham Medical Research 
Institute.3  The compounds were tested by using β-arrestin assays to identify antagonists 
of GPR55.3  This led to the identification of three potent antagonist scaffolds of GPR55: 
ML191,  ML192, and ML193 with  IC50 values of 1.08 (±0.03) μM, 0.70 (±0.05) μM, 
 
Figure 1. GPR55 Receptor, with the Disulfide Bridges Depicted.  Reprinted 
with permission from Biochemistry.  Copyright 2013 American Chemical 
Society.3 
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and 0.22 (±0.03) μM,  respectively (Figure 2).3 Docking studies were then completed by 
Dr. Reggio’s research group on the three antagonist scaffolds.3 
 
 
 
The docking studies used a homology model of GPR55 in the active and inactive 
states, which are based off of the β-adrenergic receptor.  There were two disulfide bridges 
on GPR55 which are between residues C10 and C260 and residues C3.25, and C168 
(Figure 1).iii The other two key structural features on GPR55 were the ionic lock and 
“toggle switch” residues.  Those residues had vital roles on the receptor when an 
antagonist or agonist binds.  The “toggle switch” was on TMH3 and TMH6, consisting of 
residues M3.36 and M6.48.iii The ionic lock is a hydrogen bond that occurs between 
R3.50 and Q6.30.iii When the receptor is activated by an agonist, the toggle switch 
							                   CID 23612552          CID 1434953 CID12161822 
                         ML 191              ML 192                   ML 193 
IC50                1.08 ± 0.03 μM         0.70 ± 0.05 μM        0.22 ± 0.03 μM 
 
Figure 2. Structures of GPR 55 Antagonists.3 
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residues are rotated away from each other due to the straightening of TMH6.iii This 
caused the breaking of the ionic lock and allowed for the G-protein to bind.   
The docking studies on antagonist ML192 showed the toggle switch residue 
M3.36 and M6.48 had interactions that will prevent the straightening of TMH6 and, 
therefore, ML192 acted as an antagonist (Figure 3).iii There were three hydrogen bonding 
interactions that are shown in yellow in Figure 3. The hydrogen bonding interaction 
between ML192 and K2.60 accounts for the majority of the interaction.3 The hydrogen 
bonding to K2.60 used the most electronegative region of ML192 according to the 
electrostatic potential maps (Figure 4).3  The other hydrogen bonding interactions that 
occurred were between  Q7.36 and both K2.60 and ML192.3  All of the docking studies 
completed on ML191, ML192, and ML193 showed similar interactions due to the 
similarities in the structure and the electrostatic potential maps (Figure 4).3 
 
	
	
5
 
 
 
 
Figure 3. Antagonist, ML192, Docked into GPR55 Receptor, Toggle Switch 
Residues are Shown in Purple.  Reprinted with permission from Biochemistry.  
Copyright 2013 American Chemical Society.3 
Head	Region	
 
Figure 4. Electrostatic Potential Map of ML191, ML192, and ML193 (from left to 
right).  Reprinted with permission from Biochemistry.  Copyright 2013 American 
Chemical Society.3 
Tail	Region	
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As Shown in Figure 4, these compounds have three similar structural features: a 
head region, a linear portion, and an aromatic, typically heteroaromatic portion.  The 
head region interacts with the extracellular loops of the receptor.3The linear region 
contains the most electronegative portion which contributed to the majority of the 
docking interaction.3 The aromatic or heterocyclic portion, or tail region, interacts with 
the bottom of the binding pocket of GPR55.3  All of these structural features are seen in 
Figure 4.   
Compound ML192 was the focus scaffold of the research herein. Analogs were 
typically synthesized on a 10 mg scale and submitted for biological testing by Dr. Abood 
at Temple University.  The analogs of ML192 will further elucidate interactions between 
the receptor and the analog.  The goal of the research was to find analogs that are more 
potent than the parent compound (ML192).   
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CHAPTER	II	
	
SYNTHESIS	OF	GPR55	ANTAGONISTS	
 
 
2.1	 Aims	of	Research	
	
	
ML192 was the parent compound (1) that diversification was focused on, due to 
the fact that ML193 has many commercial analogs available, and preliminary results of 
scaffold ML191 showed no promising potent antagonist of GPR55 when diversification 
of analogs was completed (Figure 1).7 Therefore, the synthesized analogs focused on 
diversification of ML192 (1). The analogs synthesized will focus on diversification of the 
head region (Figure 4; Table 1).  The goal was to synthesize a more potent analog and 
decipher major or minor interactions between the analog and receptor. For all the analogs 
synthesized, the furoyl piperazine remained constant due to the fact that when the furan 
was replaced with a thiophene or 1-methyl-1H-pyrrole the IC50 ranges increased (Table 
2). 
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Table 1. Parent Compound and Analogs of the Compound 
 
 
Analog 1 
ML192 
Parent Compound 
Aim 1 Aim 2 Aim 3 
Analog 2 
Analog 3 
Analog 4 
Analog 5 
 
Analog 6 
 
 
Table 2. Diversification of the Piperazine 
STRUCTURE IC50 Value 
 
3.7-10 μM 
 
13-14 μM 
 
 
The aims of this thesis are as to synthesize a small library of compounds to obtain 
more structure-activity relationships for ML192. Analogs 2-3 were designed to see the 
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effect of methyl groups at position 7 (Aim 1).  Analogs 4-5 showed the effect of an 
aromatic group (Aim 2).  Analog 6 focused on the effect of a bicycle instead of a tricycle 
(Aim 3).  The synthesis and resulting activities will be described in the subsequent 
sections.    
Synthesis of the analogs was accomplished through a coupling of furoyl 
piperazine (in red) and chloropyrimidine (in blue, Scheme 1).  The coupling was 
performed through a nucleophilic aromatic substitution reaction.  The furoyl piperazine 
chain remained a constant for all five analogs synthesized.   
 
 
 
 
2.2	 Synthesis	of	Furoyl	Piperazine		
	
	
The furoyl piperazine was synthesized in two steps from commercially available 
starting materials (Scheme 2).  The 1-Boc-piperazine (7) was reacted with 2-furoyl 
chloride (8) and yielded a 73% yield of a furoyl boc protected piperazine (9).8  The 
deprotection of the Boc group was accomplished through thermolysis, which yielded a 
76% of furoyl piperazine chain 10.9  Furoyl piperazine 10 was reacted in a nucleophilic 
aromatic substitution reaction (Scheme 1).  
	
 
Scheme 1. The Nucleophilic Aromatic Substitution Reaction Completed to 
Couple the Two Fragments.   
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2.3	 Aim	1‐	Synthesis	of	Methyl	Analogs	
	
	
Aim 1 was the synthesis of analogs 2 and 3.  The analogs were synthesized 
through a nucleophilic aromatic substitution reaction in which furoyl piperazine (10) was 
reacted with a chloropyrimidine.  The chloropyrimidine core was synthesized in three 
reactions from commercially available starting material.     
For the synthesis of analog 2, 4-methyl-cyclohexanone (11) was reacted in a 
Gewald reaction resulting in amino ester 12 that underwent a cyclization using 
hydrochloric acid and acetonitrile yielding pyrimidinone 13 (Scheme 3).10, 11  The last 
reaction was the conversion of the pyrimidinone to the chloropyrimidine (14).12  The 
chloropyrimidine (14) and furoyl piperazine (10) was reacted in a nucleophilic aromatic 
substitution reaction resulting in analog 2.12   
	
 
Scheme 2. Synthesis of the Furoyl Piperazine Required for all Analogs. 
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Unlike analog 2, the ketone required for analog 3 was synthesized through an acid 
catalyzed Robinson annulation reaction of isobutyraldehyde (15) and methyl-vinyl ketone 
(16) yielding 4,4-dimethyl-cyclohex-2-enone (17; Scheme 4).13, 14  The alkene was then 
hydrogenated using palladium on carbon reaction yielding 4,4,-dimethyl cyclohexanone 
(18).  The ketone (18) then underwent a Gewald reaction yielding amino ester 19 which 
was then cyclized to a pyrimidinone (20).  The pyrimidinone (20) was then reacted with 
phosphorus (IV) oxychloride (POCl3) that formed the chloropyrimidine (21), required for 
the nucleophilic aromatic substitution reaction.  
	
	
Scheme 3. Synthesis of the Chloropyrimidine Required for Analogs 2. 
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2.4	 Aim	2‐	Synthesis	of	Aromatic	Analogs		
	
	
Both analogs 4 and 5 were synthesized in a series of four reactions (Scheme 5).    
The first reaction is the Gewald reaction that used ketone 22 or 11 and formed amino 
ester 23 or 12.  Those were then oxidized using DMSO which yielded aromatic amino 
ester 24 or 25, which were then cyclized to pyrimidinones 26 or 27.15  The carbonyl 
oxygen of the pyrimidinone was converted to a chloride and yielded an aromatic 
chloropyrimidine, 28 or 29.  The aromatic chloropyrimidine (28 or 29) was then reacted 
in a nucleophilic aromatic substitution reaction which yielded analogs 4 or 5.  
	
	
Scheme 4. Synthesis of the Chloropyrimidine Required for Analogs 3. 
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A)  
B)  
	
Scheme	5.	A)	Synthesis	of	Analog	4	B)	Synthesis	of	Analog	5.	
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	2.5	 Aim	3‐	Synthesis	of	Bicycle	Analog	
	
	
 The final analog (6) requires the synthesis of a bicycle instead of the tricycle that 
is seen in analogs 2, 3, 4, and 5.  The bicycle will be synthesized in a two-step reaction 
(Scheme 6).  The first reaction reacted 2-aminopyridine-3-carboxylic acid (30) with 
dimethylacetamide (DMA), ammonium acetate, and acetic anhydride to generate 
pyrimidinone 31.16  The pyrimidinone will then be chlorinated using POCl3, yielding a 
bicycle (32) that will undergo a nucleophilic aromatic substitution reaction. The 
chlorination and nucleophilic aromatic substitution reactions are still being optimized. 
 
 
  
	
	
Scheme 6. Synthesis of the Aromatic Bicycle Core Required for Analog 6. 
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2.6	 Biological	Activity	Results		
	
	
There were a total of five compounds, ML192 and analogs 2-5, that were 
synthesized and submitted for biological activity.  The results that were obtained from 
Dr. Abood’s group are seen in Table 2.  The results showed that analog 3 has the most 
promising results with the lowest IC50 value range of 0.16-1.4 μM.  This is an indication 
that having a dimethyl at position 7 is preferred, over no methyl (analog 1) or one methyl 
group (analog 2; Figure 5).  The IC50 value of analog 2 represents a racemic mixture of 
the chiral center at position 7 (Figure 5).   
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Table 3. Biological Activity for Synthesized Analogs 
PARENT COMPOUND ACTIVITY FROM LITERATURE3 
0.70 ± 0.05 μM 
ANALOG STRUCTURE IC50 
1 
 
7.84 μM 
2 0.5-7.1 μM 
3 0.16-1.4 μM 
4 
Sent for testing 
awaiting results 
5 
Sent for testing 
awaiting results 
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2.7		 Structure	Activity	Relationships	Study		
	
	
From the data obtained, and diversification that was completed on ML192, there 
are four major changes that were seen (Figure 6). Three of the changes will focus on the 
diversification on the “head” region and the last will be on the “tail” region of the 
ML192.  Prior analogs showed the importance of the furan over a thiophene or pyrrole 
ring.  These were the only changes that were completed on the “tail” portion of the 
analog (Figure 4, Table 2).   
There are a total of four different analogs that focused on diversification of the 
cyclohexene.  These modifications will be used to determine the effect of a methyl group 
(analogs 2 and 3) and the effect of aromaticity (Figure 6, analogs 4 and 5).   
For the addition of a methyl group at position 7, a dimethyl is preferred over a 
single methyl for the following reasons (Figure 5).  The compound with a methyl group 
(analog 2) has a chiral center and pharmaceutical companies prefer the synthesis of 
achiral compounds or a synthesis that will result with a single enantiomer. Due to the fact 
that the dimethyl analog (analog 3) has a similar, if not improved, activity compared to 
the monomethyl compound, a dimethyl group is preferred to remove the complexity of 
	
 
Figure 5. Position7 on Analogs 2 and 3.  
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the chirality.  The addition of the methyl group showed that there are van der Waals 
interactions that occur between the receptor and the analog, which will be confirmed 
through subsequent computational studies.   
The second change to the cyclohexene will show the effect of aromaticity for the 
tricyclic core (Figure 6).  The cyclohexene ring of ML192 is transformed to a benzene 
ring for analogs 4 and 5.  Analog 5 has a methyl group it will be interesting to compare 
the results of assay to analogs 2 and 3.  The aromatic ring will show if there are any π-
stacking or cation  π-interactions that occur between the analog and GPR55.   
When comparing the activities of analogs 2, 3, 4, and 5, three observations can be 
made. The first is that alkylation of the 7-position is desirable as shown by analogs 2 and 
3.  The second will be whether or not cyclohexene is preferred over a benzene ring.  The 
third change will determine the importance of the bicycle and the cyclohexene ring.  If 
the activity of analog 6 was to decrease compared to the parent compound, then the 
cyclohexene ring is preferred.  This would mean a tricycle is preferred over a bicycle 
(Figure 6).   
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Figure 6.  Summary of Structure-Activity Relationship on ML-192.   
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CHAPTER	III	
	
EXPERIMENTAL	AND	CHARACTERIZATION	
 
 
3.1		 General	Information		
	
	
All the reactions performed are under anhydrous conditions, which were 
performed using dry solvents in oven dried glassware under a nitrogen gas atmosphere.  
All the reagents and solvents were obtained commercially unless otherwise stated.  
Chromatographic purification was performed using silca gel (60 Å, 32-63 μm) unless 
otherwise stated.  NMR spectra were recorded using JOEL ECA spectrometer (500 MHz 
for 1H, 125 MHz for 13C) or JOEL ECS spectrometer (400 MHz for 1H, 100 MHz for 
13C).  All NMRs were run at 25 °C unless otherwise stated.  Coupling constants, J, are 
reported in hertz (Hz) and multiplicities are listed as singlet (s), doublet (d), triplet (t), 
doublet of doublet (dd), multiplet (m), etc. High resolution mass spectra were acquired on 
a ThermoFisher Scientific LTQ Orbitrap XL MS system.   
 
3.2		 Synthesis	and	Characterization	of	Amino	Esters		
	
	
All the Gewald reactions were run under the same conditions using a variety of 
different cyclohexanone derivatives (11, 18, and 22).  
Synthesis of ethyl 2-amino-4, 5,6,7-tetrahydrobenzo [b] thiophene-3-carboxylate 
(synthesis of amino ester 24).10,11 
	
	
21
To an oven dry 50 mL round bottom flask were added ethylcyanoacetate (3.77 
mL, 30.5 mmol), sulfur (0.978 g, 30.5 mmol), cyclohexanone (22) (3.29 mL, 30.5 mmol), 
diethyl ether (6.10 mL, 5.0 M), and diethyl amine (0.30 mL, 30.5 mmol).  The flask was 
stirred under inert atmosphere at room temperature for 12 hours.  The addition of the 
diethylamine turned the reaction red.  The desired product (amino ester 23) precipitated 
out of solution and was obtained through a filtration with cold water.  There was a 62% 
yield of yellow solid (4.66 g, 20.7 mmol), which was confirmed by 1H NMR as compared 
with literature data.17 
Synthesis of ethyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylate (synthesis of amino ester 12). 10,11  
 The synthesis of amino ester 12, used ketone 11 (2.42 mL, 26.8 mmol), under the 
same conditions mentioned above (synthesis of amino ester 23).  Amino ester 12 was 
synthesized in 81% yield, of an orange solid (5.27 g, 22.0 mmol), which was confirmed 
by 1H NMR.18 
Synthesis of ethyl 2-amino-6,6-dimethyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-
carboxylate (synthesis of amino ester 19). 10,11  
The synthesis of amino ester 19 was completed using ketone 18 (0.99 g, 7.89 
mmol).  Using the same reaction condition mentioned above (synthesis of amino ester 
23).  Amino ester 19 was synthesized in 45% yield, of a red solid (0.89 g, 0.352 mmol), 
which was confirmed by 1H NMR.  
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1H NMR (400 MHz, CDCl3) δ 5.91 (br. s., 2H), 4.24 (q, J = 6.9 Hz, 2H), 2.72 - 2.64 (m, 
2H), 2.48 (t, J = 6.0 Hz, 2H), 1.80 - 1.68 (m, 4H), 1.32 (t, J = 7.1 Hz, 3H) ppm. 
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1H NMR (400 MHz, CDCl3) δ 5.93 (br. s, 2H), 4.24 (q, J = 6.9 Hz, 2H), 2.85 (td, Jt = 
2.9, Jd  = 17.6 Hz, 1 H), 2.46 - 2.64 (m, 2H), 2.01 - 2.22 (m, 1H), 1.74 - 1.96 (m, 2H), 1.23 
- 1.42 (m, 4H), 1.02 (d, J = 6.4 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3) δ 166.3, 161.9, 132.2, 117.3, 105.7, 59.5, 32.7, 31.2, 29.6, 
26.9, 21.6, 14.6 ppm. 
FTMS ESI: C12H18NO2S [M+H]+, Calculated:  240.1058 g/mol, Found: 240.1048 g/mol. 
 
 
	
	
24
 
 
 
 
1H NMR (400 MHz, CDCl3) δ 5.91 (br. s, 2H), 4.24 (q, J = 6.9 Hz, 2H), 2.68 (tt, J = 6.4, 
1.8 Hz, 2H), 2.23 - 2.28 (m, 2H), 1.47 (t, J = 6.4 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H), 0.97 
(s, 6H) ppm. 
13C NMR (100 MHz, CDCl3) δ 166.3, 161.9, 131.1, 117.1, 105.6, 59.5, 38.1, 35.8, 30.3, 
27.9, 24.7, 14.6 ppm. 
FTMS ESI: C13H20NO2S [M+H]+, Calculated: 254.1215 g/mol Found: 254.1202 g/mol. 
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3.3		 Synthesis	and	Characterization	of	Aromatic	Amino	Ester	Derivatives	15	
 
 
Synthesis of ethyl 2-aminobenzo[b]thiophene-3-carboxylate (aromatic amino ester 
24) 
To an oven dry 15 mL round bottom flask were added amino ester 23 (1.09 g, 
4.84 mmol) and dimethyl sulfoxide (DMSO) (5.0 mL, 0.968 M) and it was heated at 190 
°C for 18 hours.  The solution was cooled to room temperature and separation was 
completed using ethyl acetate and water, and the organic layer was dried with anhydrous 
sodium sulfate.  Chromatography was completed using neutral aluminum oxide (20:80 
mixture of ethyl acetate: hexane) in order to obtain aromatic amino ester 24 (0.0519 g, 
0.235 mmol) at a 5% yield of an orange solid. 
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1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.30 (t, 
J = 7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 4.40 (q, J = 7.3 Hz, 2H), 1.50 - 1.41 (m, 3H) 
ppm. 
13C NMR (100 MHz, CDCl3) δ 166.4, 164.2, 137.1, 128.7, 125.5, 122.5, 121.4, 100.1, 
60.0, 40.9, 14.7 ppm. 
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Synthesis of ethyl 2-amino-6-methylbenzo[b]thiophene-3-carboxylate (aromatic 
amino ester 25)15 
To an oven dry 15 mL round bottom flask were added amino ester 12 (1.13 g, 
4.73 mmol) and dimethyl sulfoxide (DMSO) (5.0 mL, 0.946 M) and was heated at 190 
°C for 18 hours, then reacted at room temperature for three days.  Separation was 
completed using ethyl acetate and water, and the organic layer was dried with anhydrous 
sodium sulfate.  Chromatography was completed using neutral aluminum oxide (20:80 
mixture of ethyl acetate: hexane) in order to obtain aromatic amino ester 25 (0.350 g, 
1.48 mmol) at a 31% yield of an orange solid.   
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1H NMR (400 MHz, CDCl3)  7.95 (d, J = 8.2 Hz, 1 H), 7.30 (s, 1 H), 7.11 (d, J = 8.2 
Hz, 1 H), 4.39 (q, J = 7.2 Hz, 2 H), 2.42 - 2.34 (m, 3 H), 1.49 - 1.40 (m, 3 H) ppm. 
FTMS ESI: C12H13NO2S [M+H]+, Calculated: 236.3090 g/mol, Found: 236.0736 g/mol. 
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3.4		 Synthesis	and	Characterization	of	Pyrimidinone	Derivatives		
	
	
Pyrimidinone 13 and 19 were synthesized using the same reaction conditions.  
However, pyrimidinones 26 and 27 were synthesized using different conditions.  
Precaution concentrated hydrochloric acid is used for these reaction conditions and is 
extremely corrosive.   
Synthesis of 2,7-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-
one (Pyrimidinone 13).11  
Amino ester (12) (0.564 g, 2.10 mmol) was obtained and reacted in an oven dry 
microwave vial.  Hydrochloric acid (1.40 mL, 16.7 mmol, 12.1 M) and acetonitrile (1.24 
mL, 38.4 mmol) were added to the vial under inert atmosphere.  The reaction was then 
placed in the microwave at 100 °C for 75 minutes.   The product precipitated out of 
solution and is obtained through a filtration using cold water.  There was a 65% yield of 
(pyrimidinone 13) as a white solid (0.36 g, 1.54 mmol).  
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Synthesis of 2,7,7-trimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-
4(3H)-one (Pyrimidinone 19).11 
The synthesis of pyrimidinone 19, used amino ester 19 (0.20 g, 0.79 mmol), under 
the same conditions mentioned above (synthesis of pyrimidinone 13).  Pyrimidinone 19 
was synthesized in 80% yield, as an off white solid (0.152 g, 0.613 mmol), which was 
confirmed by 1H NMR.  
 
 
 
 
1H NMR (400 MHz, CDCl3)   10.78 - 10.55 (m, 1H), 3.24 - 3.10 (m, 1H), 2.91 - 2.78 
(m, 2H), 2.50 (s, 3H), 2.43 - 2.31 (m, 1H), 2.04 - 1.87 (m, 2H), 1.50 - 1.39 (m, 1H), 1.09 
(d, J = 6.4 Hz, 2H) ppm. 
13C NMR (100 MHz, CDCl3) δ 167.1, 147.8, 130.4, 126.4, 60.6, 32.5, 31.2, 29.3, 26.3, 
23.9, 21.5, 14.4 ppm. 
FTMS ESI: C12H15N2OS [M+H]+, Calculated: 235.0905 g/mol, Found: 235.0895 g/mol. 
 
 
	
	
32
 
	
	
33
 
 
 
 
 
1H NMR (400 MHz, CDCl3)  10.47 - 10.04 (m, 1H), 3.08 - 2.90 (m, 2H), 2.52 (s, 2H), 
2.16 (s, 3H), 1.58 (s, 2H), 1.02 (s, 6H) ppm. 
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Synthesis of 2-methylbenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (Pyrimidinone 
26).11 
Amino ester (24) (0.052 g, 0.232 mmol) was reacted in an oven dry microwave 
vial with hydrochloric acid (0.20 mL, 2.42 mmol, 12.1 M) and acetonitrile (0.4 mL, 7.66 
mmol) under inert atmosphere.  The reaction was then sealed and heated in the 
microwave at 100 °C for 75 minutes.   The product precipitated out of solution and is 
obtained through a filtration using cold water.  Chromatography (using initially hexane, 
then ethyl acetate) was completed in order to obtain pyrimidinone 26 (0.019 g, 0.089 
mmol) at a 37% yield of a tan solid.  
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Synthesis of 2,7-dimethylbenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (Pyrimidinone 
27).11Amino ester (24) (0.172 g, 0.722 mmol) was reacted in an oven dry microwave vial 
with hydrochloric acid (0.45 mL, 5.45 mmol, 12.1 M) and acetonitrile (0.8 mL, 15.3 
mmol) under inert atmosphere.  The reaction was then sealed and heated in the 
microwave at 100 °C for 75 minutes.   The product precipitated out of solution and is 
obtained through a filtration using cold water.  Chromatography (5:95 mixture of ethyl 
acetate: hexane) was completed in order to obtain pyrimidinone 27 (0.034 g, 0.144 mmol) 
at a 24% yield of a tan solid. 
  
 
 
1H NMR (500 MHz, CDCl3) δ  12.66 - 12.12 (m, 1H), 8.66 - 8.50 (m, 1H), 7.90 - 7.80 
(m, 1H), 7.61 - 7.51 (m, 1H), 7.52 - 7.44 (m, 1H), 2.69 (s, 3H) ppm. 
13C NMR (125 MHz, CDCl3) δ 168.0, 160.7, 156.0, 135.6, 133.7, 126.1, 124.7, 122.4, 
115.8, 29.5, 21.9 ppm. 
FTMS ESI: C11H9N2OS [M+H]+, Calculated: 217.04 g/mol, Found: 217.0427 g/mol. 
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1H NMR (400MHz ,DMSO-d6) δ 8.26 (d, J = 7.8 Hz, 1H), 7.80 (s, 1H), 7.31 (dd, J = 
0.9, 8.2 Hz, 1H), 2.41 (s, 3H), 2.39 (s, 3H) ppm. 
 13C NMR (101MHz ,DMSO-d6) δ 166.4, 159.0, 157.2, 136.3, 134.5, 131.4, 127.7, 
124.1, 122.5, 115.7, 21.8, 21.6 ppm. 
FTMS ESI: C12H11N2OS [M+H]+, Calculated: 231.0592 g/mol, Found: 231.0583 g/mol. 
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3.5		 Synthesis	and	Characterization	of	Chloropyrimidine	Derivatives	12	
	
	
 The synthesis of chloropyrimidine derivatives (14, 21, 28, 29, and 32) was 
completed using the same procedure.  Precautions for this reaction are POCl3 is toxic and 
needs to be handled with care also when quenching the reaction with KOH it is 
exothermic use caution and cold KOH.  
Synthesis of 4-chloro-2,7-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine (chloropyrimidine 14).12 
The pyrimidinone (13; 0.190 g, 0.808 mmol) was reacted with POCl3 (0.56 mL, 4.44 
mmol) in the microwave for 3.5 hours at 150 °C. Separation was completed using cold 
aqueous 1M KOH and ethyl acetate, and the organic layer was dried with anhydrous 
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sodium sulfate.  The product (18) is concentrated down and obtained at 94% yield as a 
red-orange solid (0.084 g, 0.33 mmol). 
Synthesis of 4-chloro-2,7,7-trimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine (chloropyrimidine 21).12 
 The synthesis of chloropyrimidine 21 used pyrimidinone 20 (0.024 g, 0.098 
mmol), under the same conditions mentioned above (synthesis of chloropyrimidine 14).  
Chloropyrimidine 21 was synthesized in a 93% yield, as a brown solid (0.024 g, 0.091 
mmol). 
Synthesis of 4-chloro-2-methylbenzo[4,5]thieno[2,3-d]pyrimidine (chloropyrimidine 
26).12 
The synthesis of chloropyrimidine 26 used pyrimidinone 24 (0.019 g, 0.087 
mmol), under the same conditions mentioned above (synthesis of chloropyrimidine 14).  
Chloropyrimidine 26 was synthesized in a 61% yield, as a yellow solid (0.012 g, 0.053 
mmol). 
Synthesis of 4-chloro-2,7-dimethylbenzo[4,5]thieno[2,3-d]pyrimidine 
(chloropyrimidine 27).12 
The synthesis of chloropyrimidine 27 used pyrimidinone 25 (0.034 g, 0.149 
mmol), under the same conditions mentioned above (synthesis of chloropyrimidine 14).  
Chloropyrimidine 27 was synthesized in a 94% yield, as a brown solid (0.035 g, 0.141 
mmol). 
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1H NMR (400 MHz, CDCl3) δ 3.18 - 3.30 (m, 1H), 2.85 - 3.00 (m, 2H), 2.75 (s, 3H), 
2.40 - 2.51 (m, 1H), 1.93 - 2.09 (m, 2H), 1.43 - 1.54 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H) 
ppm. 
13C NMR (100 MHz, CDCl3) δ 169.6, 161.8, 152.9, 137.7, 126.6, 126.0, 33.9, 30.5, 
29.0, 26.1, 25.4, 21.5 ppm. 
 FTMS ESI: C12H14ClN2S [M+H]+, Calculated: 253.0566 g/mol, Found: 253.0556 
g/mol. 
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1H NMR (400 MHz, CDCl3) δ 3.05 (t, J = 6.4 Hz, 2H), 2.76 (s, 3H), 2.61 (s, 2H), 1.64 
(t, J = 6.6 Hz, 2H), 1.04 (s, 6H) ppm. 
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1H NMR (400 MHz, CDCl3) δ 8.74 - 8.66 (m, 1H), 7.95 - 7.86 (m, 1H), 7.64 - 7.54 (m, 
2H), 2.84 (s, 3H) ppm.  
13C NMR (100 MHz, CDCl3) δ 171.6, 164.3, 154.1, 136.3, 130.4, 128.2, 126.1, 125.6, 
123.0, 122.3, 25.6 ppm. 
FTMS ESI: C11H8ClN2S [M+H]+, Calculated: 235.0097 g/mol, Found: 235.0089 g/mol. 
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1H NMR (400 MHz, CDCl3) δ 8.52 (d, J = 8.2 Hz, 1H), 7.68 (s, 1H), 7.37 (d, J = 8.2 Hz, 
1H), 2.82 (s, 3H), 2.52 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3) δ 170.5, 164.2, 153.7, 139.2, 136.9, 127.8, 127.2, 125.3, 
123.1, 122.5, 25.7, 21.9 ppm. 
FTMS ESI: C13H12ClN2S [M+H]+, Calculated: 249.0253 g/mol, Found: 249.0244 g/mol. 
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3.6		 Synthesis	and	Characterization	of	Pyrido‐[2,3‐E]‐Pyrimid‐4‐One	
	
	
Synthesis of 2-methylpyrido[3,2-d]pyrimidin-4(1H)-one (Pyrido-[2,3-e]-pyrimid-4-
one 31).16 
2-Aminonicotinic acid (0.050 g, 0.362 mmol), ammonium acetate (0.084 g, 1.09 
mmol), acetic acid (0.16 mL, 1.45 mmol), and dimethylacetamide (DMA; 0.40 mL, 1.0 
M) were added to an oven dry microwave vial (0.5-2.0 mL ) under inert atmosphere.  The 
reaction was then heated in the microwave at 250 °C for 30 minutes.   Separation was 
completed using sodium chloride, water, and ethyl acetate and the organic layer was 
dried with anhydrous sodium sulfate.  Chromatography (50:50 mixture ethyl acetate: 
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hexane) was completed in order to obtain pyrido-[2,3-e]-pyrimid-4-one 31 (0.078 g, 
0.481 mmol), at a 28% yield of a yellow solid, which was confirmed by 1H NMR.16 
 
	
 
1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 2.3 Hz, 1H), 8.58 (dd, J = 1.6, 8.0 Hz, 1H), 
7.48 - 7.37 (m, 1H), 2.64 (s, 3H) ppm. 
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3.7		 Synthesis	and	Characterization	of	Tert‐Butyl	4‐(Furan‐2‐Carbonyl)Piperzine‐
1‐Carboxylate	8	
	
	
To a dry 50 mL round bottom flask was added 2-furylchloride (9) (1.67 mL, 16.8 
mmol) 1-bocpiperizine (10) (3.14 g, 16.8 mmol), triethylamine (2.0 mL, 0.12 M), in 20 
mL of DCM.  The reaction was left to react 24 hours at room temperature and separation 
was completed using 1M hydrochloric acid and ethyl acetate.  The product (11) was 
obtained with a 73% yield of a white solid (3.59 g, 12.8 mmol).  The 1H NMR data 
matched previously reported data.8 
 
 
 
1H NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 7.02 (d, J = 3.2 Hz, 1H), 6.48 (dd, J = 1.6, 
3.4 Hz, 1H), 3.76 (br. s, 4H), 3.55 - 3.42 (m, 4H), 1.46 (s, 9H) ppm. 
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3.8		 Synthesis	and	Characterization	of	Furan‐2‐Yl(Piperazin‐1‐Yl)Methanone	9	
	
	
To a small microwave vial was added 200 mg of furyl boc protected piperazine 
(11) and heated using a heat gun for 10 minutes for desired bubbling.  Chromatography 
was completed (50% ethyl acetate and 50% methanol) which gave a 76% yield of a 
brown oil (0.165, 0.89 mmol), the deprotected boc piperazine product (10). The 1H NMR 
data matched previously reported data.9 
 
 
 
1H NMR (400 MHz, CDCl3) δ 7.50 - 7.43 (m, 1H), 6.97 (d, J = 3.2 Hz, 1H), 6.46 (dd, J 
= 1.8, 3.7 Hz, 1H), 3.76 (br. s., 4H), 3.10 - 2.76 (m, 4H), 1.77 (br. s, 1 H) ppm. 
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3.9		 Synthesis	and	Characterization	of	Cyclohexanone	Derivative	13,	14		
	
	
Synthesis of 4,4-dimethylcyclohex-2-ene-1-one.13, 14 
A neat reaction of isoburtylaldehye (15; 10.5 mL, 166.8 mmol) and methyl vinyl 
ketone (16; 9.5 mL, 114.41 mmol) was reacted with sulfuric acid (0.05 mL).  The 
reaction was run in a dean stark trap and a yellow oil; 4,4-dimethylcyclohex-2-ene-1-one 
(17; 12.4 g, 99.8 mmol) was obtained through short distant vacuum distillation at a 45% 
yield.  The 1H NMR data matched previously reported data.13, 14 
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1H NMR (400 MHz, CDCl3) δ 6.64 (d, J = 10.1 Hz, 1H), 5.82 (d, J = 10.1 Hz, 1H), 2.58 
- 2.34 (m, 2H), 1.85 (t, J = 6.9 Hz, 2H), 1.15 (s, 6H) ppm. 
 
 
 
Synthesis of 4,4, -dimethyl-cyclohex-2-ene-1-one.13 
Caution do not place hydrogen atmosphere directly on palladium on carbon that is 
flammable, and methanol first.  To a 100 mL RBF was added ketone (1.0 g, 64.5 mmol), 
palladium on carbon (0.020 g, 50% Pd) and dry methanol (5.38 mL, 1.4 M) under an 
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inert hydrogen gas atmosphere.  The reaction then reacted for 24 hours at room 
temperature and was filtered through Celite. Ketone (18) was obtained at 90% yield of 
clear oil (0.92g, 7.25mmol). The 1H NMR data matched previously reported data.13 
 
 
 
1H NMR (400 MHz, CDCl3) δ 2.33 (t, J = 6.9 Hz, 4H), 1.66 (t, J = 6.9 Hz, 4H), 1.08 (s, 
6H) ppm. 
13C NMR (100 MHz, CDCl3) δ 212.9, 39.2 (s, 2C) 38.1 (s, 2C) 29.6 - 30.7 (m, 1C) 27.6 
(s, 2C) ppm. 
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3.10  Synthesis and Characterization of Analogs12		
	
	
The syntheses of all analogs were completed under the same reaction condition 
seen below.   
Synthesis of (4-(2,7-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-
yl)piperazin-1-yl)(furan-2-yl)methanone (Analog 2).12 
 To a dry 10 mL round bottom flask was added chloropyrimidine (14) (0.70 g, 
0.278 mmol), furoyl piperazine (10) (0.10 g, 0.555 mmol), triethylamine (0.12 mL, 0.825 
mmol), and dry methanol (5.0 mL, 0.089 M).  The reaction was then left to react for 24 
hours at room temperature.  Chromatography (20:80 mixture of ethyl acetate: hexane) is 
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then completed in order to obtain analog 2 (0.079 g, 0.199 mmol), at a 64% yield of a tan 
solid. 
  
	
	
1H NMR (500 MHz, CDCl3, 58 °C) δ 7.48 (s, 1H), 7.03 (d, J = 3.4 Hz, 1H), 6.48 (dd, J = 
1.7, 3.4 Hz, 1H), 4.06 - 3.96 (m, 2H), 3.95 - 3.86 (m, 2H), 3.53 (ddd, J = 3.2, 7.2, 12.6 
Hz, 2H), 3.38 (ddd, J = 2.9, 7.2, 12.9 Hz, 2H), 3.11 (d, J = 16.0 Hz, 1H), 2.94 (dd, J = 
5.4, 16.9 Hz, 1H), 2.80 (ddt, Jd = 2.6, 5.2 Hz Jt  = 10.7 Hz, 1H), 2.61 (s, 3H), 2.51 - 2.41 
(m, 1H), 2.08 - 1.98 (m, 1H), 1.97 - 1.90 (m, 1H), 1.48 - 1.35 (m, 1H), 1.13 (d, J = 6.3 
Hz, 3H)  ppm. 
13C NMR (100 MHz, CDCl3) δ 169.3, 161.9, 161.0, 159.4, 147.8, 143.9, 134.2, 126.3, 
118.9, 116.8, 111.5, 60.5, 50.8, 44.6, 34.0, 31.3, 29.4, 26.4, 25.6, 21.7, 14.3 ppm. 
FTMS ESI: C21H25N4O2S [M+H]+, Calculated: 397.1698 g/mol,  Found: 397.1679 
g/mol. 
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Synthesis of furan-2-yl(4-(2,7,7-trimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-yl)piperazin-1-yl)methanone (Analog 3).12  
To a dry 5 mL round bottom flask was added chloropyrimidine (21) (0.038 g, 
0.143 mmol), furoyl piperazine (10) (0.0515 g, 0.0515 mmol), triethylamine (0.06 mL, 
0.429 mmol), and dry methanol (2.6 mL, 0.055 M).  The reaction was then left to react 
for 24 hours at room temperature.  Chromatography (20:80 mixture of ethyl acetate: 
hexane) is then completed in order to obtain analog 3 (0.044 g, 0.107 mmol), at a 75% 
yield of a tan solid. 
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1H NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 7.03 (d, J = 3.2 Hz, 1H), 6.49 (dd, J = 1.8, 
3.2 Hz, 1H), 3.97 (br. s, 4H), 3.52 - 3.24 (m, 4H), 2.91 (t, J = 6.2 Hz, 2H), 2.61 (s, 3H), 
1.57 (t, J = 6.2 Hz, 2H), 1.35 - 1.16 (m, 2H), 1.13 - 0.93 (m, 6H)  ppm. 
13C NMR (100 MHz, CDCl3) δ 169.4, 162.1, 161.0, 159.4, 147.9, 143.9, 134.1, 125.1, 
119.0, 116.8, 111.5, 51.0, 39.5, 35.9, 31.7, 30.1, 28.1 (2C), 25.6, 23.8, 22.8, 14.3 ppm. 
FTMS ESI: C22H27N4O2S [M+H]+, Calculated: 411.18492 g/mol Found: 411.18497 
g/mol. 
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Synthesis of furan-2-yl(4-(2-methylbenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-
1-yl)methanone (Analog 4).12 
To a dry 0.5-2.0 mL microwave vial was added chloropyrimidine (28) (0.012 g, 
0.053 mmol), furoyl piperazine (10) (0.019 g, 0.106 mmol), triethylamine (0.02 mL, 
0.159 mmol), and dry methanol (1.0 mL, 0.053 M).  The reaction was then left to react 
for 24 hours at room temperature then 24 hours at 50 °C.  Chromatography (hexane) is 
then completed in order to obtain analog 3 (0.0036 g, 0.0095 mmol), at an 18% yield of a 
brown solid. 
	
	
64
	
	
1H NMR (400 MHz, CDCl3) δ 8.01 - 7.93 (m, 1H), 7.91 - 7.84 (m, 1H), 7.55 - 7.43 (m, 
3H), 7.10 - 7.03 (m, 1H), 6.53 - 6.47 (m, 1H), 4.11 - 3.95 (m, 4H), 3.69 - 3.58 (m, 4H), 
2.73 - 2.70 (m, 3H) ppm	
13C NMR (100 MHz, CDCl3) δ 170.9, 164.8, 161.7, 158.9, 148.0, 143.7, 135.3, 131.2, 
126.5, 125.2, 124.2, 123.1, 116.8, 113.0, 111.2, 48.9, 29.8, 25.8 ppm	
FTMS ESI: C20H18N4O2S [M+H]+, Calculated: 379.1228 Found: 379.1216 
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Synthesis of (4-(2,7-dimethylbenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-
yl)(furan-2-yl)methanone (Analog 5).12  
To a dry 5.0-20.0 mL microwave vial was added chloropyrimidine (29) (0.035 g, 
0.141 mmol), furoyl piperazine (10) (0.051 g, 0.282 mmol), triethylamine (0.03 mL, 
0.423 mmol), and dry methanol (2.6 mL, 0.055 M).  The reaction was then left to react 
for 24 hours at room temperature then 24 hours at 50 °C.  Chromatography (hexane) is 
then completed in order to obtain analog 3 (0.0054 g, 0.014 mmol), at a 10% yield of a 
brown solid. 
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1H NMR (400 MHz, CDCl3) δ  7.87 - 7.79 (m, 1H), 7.69 - 7.64 (m, 1H), 7.52 - 7.43 (m, 
1H), 7.36 - 7.30 (m, 1H), 7.12 - 7.03 (m, 1H), 6.53 - 6.47 (m, 1H), 4.08 - 3.93 (m, 4H), 
3.68 - 3.52 (m, 4H), 2.69 (s, 3H), 2.51 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3) δ 170.6, 163.7, 161.6, 159.2, 147.3, 143.9, 136.8, 135.6, 
129.2, 126.7, 124.1, 123.1, 117.0, 113.2, 111.6, 51.0, 49.0 (2C), 25.9 (2C), 21.3 ppm. 
FTMS ESI: C22H21N4O2S [M+H]+, Calculated: 393.1385 g/mol, Found: 393.1371 g/mol. 
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